Impact of erlotinib treatment on symptoms and quality of life in patients with advanced non-small-cell lung cancer / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 469-472, 2008.
Artículo
en Chino
| WPRIM
| ID: wpr-357397
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the impact of erlotinib as a second or third line treatment on the symptoms and quality of life (QOL) in patients with advanced non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>Fifty patients with stage III b and IV NSCLC, treated previously with at least one regimen of platinum-based chemotherapy, received 150 mg of erlotinib orally, once a day till disease progression. QOL was assessed by European Organization for Research and Treatment of Cancer QLQ-C30 and the lung cancer module (QLQ-LC13). The primary end points for QOL analysis were time to deterioration of three common lung cancer symptoms cough, dyspnea and pain.</p><p><b>RESULTS</b>Among 47 evaluable cases, there were partial remission (PR) in 18 cases, stable disease (SD) in 21 cases, and progressive disease (PD) in 8 cases. After two cycles of treatment, the mean scores of global QOL and all 5 functioning scales except the cognitive function increased significantly (P < 0.05). Mean scores of major general symptoms, hypodynamia and anorexia, and disease-related symptoms alleviated significantly. Both response rates of five functioning and global QOL were more than 44% after erlotinib treatment. Response rates of major general symptoms and disease-related symptoms varied from 14% to 76%. Patients with complete or partial response likely had improvement in the QOL response (P < 0.05), and the time to major symptom deterioration in those were significantly longer (P < 0.001) than that in patients with stable or even progressive disease.</p><p><b>CONCLUSION</b>Erlotinib is effective to improve not only survival, but also tumor-related symptoms and quality of life in patients with advanced NSCLC previously treated with cisplatin-contained regimens. The improvement in the quality of life is positively correlated with objective tumor response.</p>
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Patología
/
Calidad de Vida
/
Quinazolinas
/
Inducción de Remisión
/
Estudios de Seguimiento
/
Terapia Recuperativa
/
Insuficiencia del Tratamiento
/
Carcinoma de Pulmón de Células no Pequeñas
/
Progresión de la Enfermedad
/
Usos Terapéuticos
Tipo de estudio:
Estudio diagnóstico
/
Estudio observacional
/
Estudio pronóstico
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
/
Masculino
Idioma:
Chino
Revista:
Chinese Journal of Oncology
Año:
2008
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS